Anuh Pharma
79.85
-0.40(-0.50%)
Market Cap₹800.29 Cr
PE Ratio20.83
IndustryHealthcare
Company Performance:
1D-0.50%
1M-1.57%
6M-24.44%
1Y-28.34%
5Y-28.34%
View Company Insightsright
More news about Anuh Pharma
23May 25
Anuh Pharma Reports Mixed Q4 Results, Recommends Dividend
Anuh Pharma Ltd. released its Q4 FY2023-24 results, showing a 15.85% increase in revenue to ₹1,900 crore. However, net profit declined by 18.62% to ₹125 crore. The company's EBITDA margin contracted to 10.48%. Despite Q4 challenges, annual performance for FY2024 was strong with a 23.52% revenue growth and 66.02% increase in net profit. The board recommended a dividend of ₹1.50 per equity share.
Anuh Pharma
79.85
-0.40
(-0.50%)
1 Year Returns:-28.34%
Industry Peers
Sun Pharmaceutical
1,781.70
(+0.24%)
Divis Laboratories
6,391.50
(-1.10%)
Torrent Pharmaceuticals
3,687.30
(-0.92%)
Cipla
1,517.20
(-0.78%)
Dr Reddys Laboratories
1,247.20
(-0.11%)
Zydus Life Science
926.25
(-0.19%)
Lupin
2,032.00
(+0.06%)
Mankind Pharma
2,241.70
(+0.10%)
Aurobindo Pharma
1,210.10
(+0.20%)
Alkem Laboratories
5,693.00
(-0.12%)